Table of Contents  

Apixaban – another new oral anticoagulant on the horizon for atrial fibrillation

Alexander Niessner
Published in : HAMDAN MEDICAL JOURNAL ; Vol 5, No 1 (2012)
DOI : 10.7707/hmj.v5i1.109

Abstract


Anticoagulation of patients with atrial fibrillation iscrucial to prevent thromboembolic events. However,the currently used vitamin K antagonists (VKAs) havesevere disadvantages, such as an increased risk ofintracerebral bleeding or the necessity of laboratorymonitoring. Recently, new oral anticoagulants directlyinhibiting factor Xa or thrombin have been testedwhich may overcome these drawbacks. In 2011 the ARISTOTL E study testing the oral direct factor Xainhibitor apixaban was published in the New EnglandJournal of Medicine (http://www.nejm.org/doi/full/10.1056/NEJMoa1107039).

View article in  :   HTML     PDF     Flip



Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA